Equities
  • Price (EUR)1.18
  • Today's Change0.000 / 0.00%
  • Shares traded--
  • 1 Year change-13.24%
  • Beta0.5145
Data delayed at least 15 minutes, as of Mar 05 2026 15:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Shanghai Pharmaceuticals Holding Co Ltd grew revenues 5.75% from 260.30bn to 275.25bn while net income improved 20.82% from 3.77bn to 4.55bn.
Gross margin10.35%
Net profit margin2.43%
Operating margin3.49%
Return on assets2.97%
Return on equity7.70%
Return on investment8.24%
More ▼

Cash flow in CNYView more

In 2024, Shanghai Pharmaceuticals Holding Co Ltd increased its cash reserves by 15.93%, or 4.38bn. The company earned 5.83bn from its operations for a Cash Flow Margin of 2.12%. In addition the company generated 415.98m cash from investing, though they paid out 1.86bn more in financing than they received.
Cash flow per share--
Price/Cash flow per share--
Book value per share23.11
Tangible book value per share16.44
More ▼

Balance sheet in CNYView more

Shanghai Pharmaceuticals Holding Co Ltd has a Debt to Total Capital ratio of 37.47%, a higher figure than the previous year's 13.15%.
Current ratio1.32
Quick ratio1.02
Total debt/total equity0.7088
Total debt/total capital0.3747
More ▼

Growth rates in CNY

SmartText is unavailable
Div yield(5 year avg)--
Div growth rate (5 year)--
Payout ratio (TTM)19.05%
EPS growth(5 years)-3.06
EPS (TTM) vs
TTM 1 year ago
39.89
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.